Cellectar Biosciences, Inc.

Patients

Our Message to You

Every single day, we dedicate ourselves to achieving excellence in our work. Our mission is to advance our product candidates swiftly and efficiently, targeting patient populations with limited or no treatment options. At Cellectar, many of us have personally experienced the devastating impact of cancer on our own lives and the lives of our loved ones. Some of us have lost close relatives to the very cancers we are now studying in our clinical trials.

These personal experiences fuel our passion, drive, and determination to develop safe and effective treatments for cancer patients worldwide. Whether you are a 7-year-old child diagnosed with neuroblastoma or a 70-year-old adult facing Multiple Myeloma, our commitment to you remains unwavering. We strive to ensure your safety, enhance your quality of life during treatment, and most importantly, support your journey to recovery.

To learn more about our clinical studies or to learn more about our Waldenstrom’s macroglobulinemia pivotal clinical study, please visit our Clinical Studies page or visit www.wmclinicaltrial.com.

Clinical Studies Overview

Clinical studies are a fundamental necessity in the development and advancement of new treatment options for battling cancer, and you may not know it, but you could play an important role. Clinical studies need patients to participate so that they can advance through the processes necessary to potentially get a new treatment to market. Your participation in clinical studies can help create a better treatment landscape for future cancer patients.

To a lot learn more about clinical studies in general, please visit www.cancer.org and find the Clinical Studies section.

Disease Education and Patient Resources

Once you or your loved one has been diagnosed with cancer, it is essential that you learn as much as you can about the disease; this will help you make better treatment decisions. We believe in empowering patients and caregivers with both information and resources. To this end, we have assembled disease education and patient resource sections for each of the cancers included in our clinical studies and have listed them below. For more information on the cancers listed below, as well as many others, please visit www.cancer.org.

Waldenstrom's Macroglobulinemia Multiple Myeloma Pediatric and Adolescent Cancers

Waldenstrom’s macroglobulinemia

What is Waldenstrom’s macroglobulinemia?1

Waldenstrom’s macroglobulinemia (WM) is a rare, slow-growing cancer of the lymphatic system. Cancers of the lymphatic system are called lymphomas. WM is a type of lymphoma called non-Hodgkin lymphoma. Non-Hodgkin lymphoma is not a single disease; it refers to a group of different lymphomas that start in the lymphocytes (white blood cells). WM affects a specific type of white blood cell, called a B-lymphocyte or B-cell for short.

Symptoms of Waldenstrom’s macroglobulinemia2

Waldenstrom’s macroglobulinemia is a rare blood cancer that is slow growing. Because of this, it may not cause the patient to exhibit any symptoms for years. The following symptoms may appear, but are not limited to this list:

  • Weight loss
  • Fatigue
  • Bleeding from the nose or gums
  • Neuropathy in hands and/or feet
  • Fever
  • Shortness of Breath
  • Headache
  • Changes in vision
  • Confusion

Waldenstrom’s macroglobulinemia Treatment Options3

Treatment options vary widely and are based upon whether the patient is experiencing symptoms, their overall health, and what stage the patient is in. A patient’s doctor and/or care team will work with patients to decide the best way to move forward with treatment so that the cancer can be managed successfully for many years. For more information on the varying types of treatment for patients, an organization like the International Waldenstrom’s Macroglobulinemia Foundation is a great resource for both patients and caregivers.

What Patients and Caregivers Should Know about Clinical Studies for Waldenstrom’s macroglobulinemia

Often, doctors and care teams will recommend that a patient should consider participating in a clinical study as a new way to combat their Waldenstrom’s diagnosis. Clinical studies are studies that look at newly discovered cancer treatments. These studies are used to show healthcare providers how well the new treatments are working and whether there are any side effects from the treatment. There are many rules and regulations in place to protect the patient and to keep their best interests at the forefront of treatment. Because of this, the patients who decide to participate in these studies can receive these therapies prior to FDA approval. Consequently, patients who participate in clinical studies may benefit from a novel treatment and pave the way for new and improved treatments for future patients.

For more information about Cellectar Biosciences’ clinical studies for Waldenstrom’s macroglobulinemia, please visit www.wmclinicaltrial.com or www.cellectar.com/clinical-studies.

Additional Resources for Patients and Caregivers Affected by Waldenstrom’s macroglobulinemia

Housing and Travel Assistance

Resources, Organizations, and Support

Clinical Studies

Multiple Myeloma

What is Multiple Myeloma?4

Multiple myeloma is a type of blood cancer that affects plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow (the soft, spongy tissue at the center of your bones), crowding out the normal plasma cells that help fight infection. These malignant plasma cells then produce an abnormal antibody called M protein, which offers no benefit to the body and may cause tumors, kidney damage, bone destruction, and impaired immune function. The hallmark characteristic of multiple myeloma is a high level of M protein in the blood.

Multiple myeloma typically displays the most activity in bone marrow, which includes the marrow in the spine, pelvic bones, ribs, shoulders, and hips.

Symptoms of Multiple Myeloma5

Multiple Myeloma is often a slow-developing disease and in the early stages, a person may not exhibit symptoms at all. However, as the disease reaches advanced stages, the following symptoms may appear:

  • Fatigue, weakness
  • Shortness of breath
  • Weight loss
  • Nausea
  • Bone pain (most frequently in the back or ribs)
  • Bone fractures (usually in the spine) without explanation
  • Fever
  • Constipation

Multiple Myeloma Treatment Options6

Treatment options vary widely and are based upon whether the patient is experiencing symptoms, their overall health, and what stage the patient is in. A patient’s doctor and/or care team will work with patients to decide the best way to move forward with treatment so that the cancer can be managed successfully for many years. For more information on the varying types of treatment for patients, please visit www.cancer.net - the doctor-approved patient information site from ASCO.

What Patients and Caregivers Should Know About Clinical Studies for Multiple Myeloma

According to the Multiple Myeloma Research Foundation website, almost all cancer treatments available today resulted from research conducted in clinical trials. Clinical trials are vital to the development and creation of new multiple myeloma treatments, and to helping patients and doctors understand more about this rare and complex blood cancer. For many people with multiple myeloma, participation in a clinical trial may be a good option for treatment. If you are considering participating in a clinical trial, speak with your treatment team about which trial might be the best option for you or if standard treatment options may be a better choice at that point in time.

For more information about Cellectar Biosciences’ clinical studies for multiple myeloma, please visit: https://www.cellectar.com/clinical-studies.

Additional Resources for Patients and Caregivers Affected by Multiple Myeloma

Housing and Travel Assistance

Resources, Organizations, and Support

Clinical Studies

Pediatric and Adolescent Cancers

What are the cancers listed in the clinical study?7
There are several types of cancer being studied in this clinical study. They are:
  • Relapsed or Refractory Malignant Brain Cancer - This type of cancer can be aggressive and grow rapidly. It can also spread (metastasize) to other areas that are generally near the original tumor and/or to other parts of the brain.
  • Neuroblastoma - This type of cancer is caused by the uncontrolled growth of cells in a special type of nerve cell called neuroblasts. These cells are supposed to grow into functioning nerve cells but with neuroblastoma, they develop into cancer cells instead. Generally, neuroblastoma starts in the tissue in the adrenal glands on top of the kidneys of the child and can spread (metastasize) to other parts of the body.7
  • Rhabdomyosarcoma - A type of tumor that forms in the soft tissue of the body. There are two types of Rhabdomyosarcomas called embryonal and alveolar. Embryonal is generally seen in children aged five and under. Alveolar occurs in children of all ages and often affects the large muscles of the body.8
  • Ewing’s Sarcoma - A type of tumor that grows in the bones and/or in the soft tissue around bones and is generally found in the legs, pelvis, ribs, arms, or spine. It can also spread to other parts of the body as well.8
  • Osteosarcoma - A type of tumor that grows in the bones and is most often found in the wide ends of long bones like the tibia and femur. In some patients (about 15 - 20%) the cancer has spread by the time it is diagnosed.8

Pediatric and Adolescent Cancer Treatment Options9

Treatment options vary widely and are based upon whether the patient is experiencing symptoms, their overall health, and the stage of cancer. A patient’s doctor and/or care team will work with patients to decide the best way to move forward with treatment in order to successfully manage the cancer for the long term. For more information on the varying types of treatment for patients, a website like the www.cancer.net is a great resource for both patients and caregivers.

What Patients and Caregivers Should Know About Clinical Studies for Pediatric Cancers

Did you know that childhood cancer patients enter clinical studies more often than adult cancer patients? Currently, clinical studies are standard practice in cancer treatment for children, adolescents and young adults. While less than five percent of adults with cancer are enrolled in clinical studies, 60 percent of patients under age 29 diagnosed with cancer are enrolled in clinical studies. For each new clinical study that begins enrolling patients, a group of doctors, nurses and other experts propose how the treatment should be given. Many experts review the study before it is sent to the National Cancer Institute (NCI) for approval. The institutional review board (IRB) of each hospital participating in a clinical study must also approve it, in part to make sure that the rights of patients who will be enrolled in the studies are protected.10

For more information about Cellectar Biosciences’ clinical studies for these select pediatric and adolescent cancers, please visit: https://www.cellectar.com/clinical-studies.

Additional Resources for Patients and Caregivers Affected by Pediatric and Adolescent Tumors

Housing and Travel Assistance

Resources, Organizations, and Support

Clinical Studies